Using Oncolytic Viral Immunotherapy to Kill Solid Tumors with Dr. Paul Peter Tak Candel Therapeutics TRANSCRIPT
Download PDFSep 19, 2022
Dr. Paul Peter Tak is the CEO and President of Candel Therapeutics, developing innovative immunotherapies for patients with solid tumors that are difficult to treat, like brain cancer, pancreatic cancer, prostate cancer, and non-small cell lung cancer. This approach induces cell death in cancer cells at the site of...
Using Oncolytic Viral Immunotherapy to Kill Solid Tumors with Dr. Paul Peter Tak Candel Therapeutics
Sep 19, 2022
Dr. Paul Peter Tak is the CEO and President of Candel Therapeutics, developing innovative immunotherapies for patients with solid tumors that are difficult to treat, like brain cancer, pancreatic cancer, prostate cancer, and non-small cell lung cancer. This approach induces cell death in cancer cells at the site of...
Using Antibodies from Memory B Cells to Restore Immune Response to Autoimmune Oncologic and Infectious Diseases with Matthew Robinson Immunome TRANSCRIPT
Download PDFJul 19, 2022
Matthew Robinson is the Senior Vice President of R&D at Immunome, which is leveraging the information in memory B cells to target antibody therapeutics to kill tumor cells.
Matthew explains, "At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor...
Jul 19, 2022
Matthew Robinson is the Senior Vice President of R&D at Immunome, which is leveraging the information in memory B cells to target antibody therapeutics to kill tumor cells.
Matthew explains, "At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor...
Identifying Targets on Problematic T Cells to Treat Immunological Diseases with Dr. Judy Chou AltruBio TRANSCRIPT
Download PDFJul 13, 2022
Dr. Judy Chou is the President and CEO of AltruBio which is developing novel immunomodulators to treat immunological diseases such as autoimmune and inflammatory diseases. Their first-in-class agnostic antibody has a unique mechanism to regulate T cell homeostasis. Currently, there is a clinical trial for SR-aGVHD,...